Gilead Springs Further Into Oncology With Calistoga Acquisition
Dominant in HIV, the biotech pays $375 million up front for Seattle-based Calistoga and its closely-watched PI3K program.
Dominant in HIV, the biotech pays $375 million up front for Seattle-based Calistoga and its closely-watched PI3K program.